AMP 2021

The AMP 2021 Digital Experience

Virtual Corporate Workshop

Is Copy Number Quantification Enough? Rapid, Comprehensive Profiling of SMN1 and SMN2 is Possible with the AmplideX® PCR/CE SMN1/2 Plus Kit

Spinal muscular atrophy (SMA) is a leading genetic cause of infant death worldwide. While SMN1 and SMN2 copy number quantification is routinely performed to screen for and diagnose SMA, evolving carrier screening, treatment, and management data suggests testing for additional alterations may be needed.

In this workshop, we review how the AmplideX® PCR/CE SMN1/2 Plus Kit (RUO) quantifies SMN1/SMN2 copy number and detects additional variants associated with silent carrier status and disease severity – all via a simple, streamlined, and scalable testing workflow providing rapid results in under four hours.

Kendal Jensen, MD, PhD
Director of Molecular Genetic Pathology, Sharp Health

Ninad Pendse

Senior Product Manager, Asuragen



Scientific Posters

A Deep Learning-Powered Genotyping System for C9orf72 Hexanucleotide Repeat Expansions Enables High Throughput Genetic Analysis

Presenters: Ryan Routsong, Adrian Gonzalez, Lando Ringel, Jacob Ashton, Sarah N Statt, Gary J Latham and Brian C Haynes, Department of Research and Development
Asuragen, Inc., a Bio-Techne brand, Austin, TX, USA.



Verification of a Targeted PCR/CE CFTR Assay and Companion Software that Addresses 93% Mutation Prevalence across Diverse Ethnic Groups

Presenters: Connor Parker, Kevin Kelnar, Elliot Hallmark, Sarah Edelmon, Shobha Gokul, Pranesh Rao, John N Milligan and Bradley Hall
Asuragen, Inc., a Bio-Techne brand, Austin, TX, USA.



QuantideX® qPCR BCR-ABL IS Kit and ipsogen BCR-ABL1 Mbcr IS-MMR Kit Yield Highly Correlated Results

Presenter: Adrian Lara, Ion Beldorth, Keri Jefferson and Justin T Brown
Asuragen, Inc., a Bio-Techne brand, Austin, TX, USA.



Contact Us

Want to connect with Asuragen? Click HERE and complete the form to be contacted by an Asuragen representative.

Back To